News Sentiment

KRRO sentiment intelligence

Korro Bio, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 14.56 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+4.0% over one week, +25.4% over four weeks, trend active, and below fair value.

Latest direct headline Positive

Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction 4.0% Price confirming higher
Trend fit Trend active 25.4% over four weeks
Fair value -54.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 34
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
TradingView 5
Stock Titan 5
Investing.com Canada 4
www.marketscreener.com 4
Investing.com 3
simplywall.st 3
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 10
Analyst action 4
Regulatory and legal 2
Deals and strategy 2
Macro sensitivity 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 50
The Manila Times Direct company coverage

Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Korro Bio, Inc. announced the grant of non-statutory stock options to seven newly hired employees as an inducement to employment. These grants, approved by Korro’s independent Compensation Committee, were made under Korro’s 2026 Inducement Plan in accordance with Nasdaq Listing R

Tone
Positive 64/100
Event
Market update
Published
11 Jul 2026 06:10
Source
The Manila Times
TradingView Direct company coverage

Price to sales forward of Korro Bio, Inc. – NASDAQ:KRRO

This article provides a financial metric—the price to sales forward—for Korro Bio, Inc. (NASDAQ: KRRO). It indicates the company's ticker, the exchange it trades on, and that the market is currently closed. The content itself seems to be a placeholder or a partial display from a

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 05:13
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Korro Bio, Inc. – NASDAQ:KRRO

This article provides financial information for Korro Bio, Inc. (NASDAQ: KRRO), specifically focusing on its forward price-to-earnings ratio. It is a data-focused piece from TradingView, indicating that the market is closed and no trades have occurred for the stock.

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 00:41
Source
TradingView
Kavout | AI Direct company coverage

Korro Bio: Why Director Sales Temper a 'Strong Buy' Consensus

Korro Bio, a biopharmaceutical company specializing in RNA editing, faces conflicting signals, with director Jean Francois Formela's affiliated funds selling over $4 million in stock despite a "Strong Buy" consensus from Wall Street analysts. The company's innovative pipeline and

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 17:41
Source
Kavout | AI
Investing.com Nigeria Direct company coverage

Korro Bio director Formela sells $1.54m in shares By Investing.com

Korro Bio director Jean Francois Formela sold approximately $1.54 million worth of the company's common stock in early July through a Rule 10b5-1 trading plan. These sales occurred on July 2 and July 6, 2026, at weighted average prices between $13.96 and $14.03, following a 71% s

Tone
Negative 39/100
Event
Market update
Published
08 Jul 2026 17:41
Source
Investing.com Nigeria
Investing.com Direct company coverage

Korro Bio director Formela sells $1.54m in shares

Korro Bio director Jean Francois Formela sold approximately $1.54 million worth of shares in early July through a pre-arranged trading plan. These sales occurred after KRRO shares saw a 71% surge over the past six months and coincide with recent analyst upgrades and new pipeline

Tone
Neutral 50/100
Event
Analyst action
Published
08 Jul 2026 07:09
Source
Investing.com
Investing.com Canada Direct company coverage

Form 4 Korro Bio Inc For: 7 July By Investing.com

This article announces that Korro Bio Inc. (KRRO) filed a Form 4 for July 7th. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership position of company insiders. The article does no

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 22:10
Source
Investing.com Canada
Investing.com Canada Direct company coverage

Form 144 Korro Bio For: 6 July By Investing.com

This article announces the filing of Form 144 for Korro Bio on July 6th. It briefly mentions the company's stock symbol KRRO and its current performance while providing no further details about the filing itself. The article also includes various market data and other news headli

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 04:10
Source
Investing.com Canada
MSN Direct company coverage

Korro Bio, Inc. (KRRO) soars 17.6%: Is further upside left in the stock?

Korro Bio, Inc. (KRRO) experienced a significant 17.6% surge in its stock price, raising questions about its future growth potential. This movement comes amid broader market trends and the company's recent performance. Investors are now evaluating whether this momentum suggests f

Tone
Positive 73/100
Event
Market update
Published
06 Jul 2026 05:40
Source
MSN
Finviz Direct company coverage

KRRO - Korro Bio Inc Options

This article provides a detailed financial overview of Korro Bio Inc (KRRO), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists key performance metrics like insider ownership, institutional ownership, profitability, a

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 03:40
Source
Finviz
www.marketscreener.com Direct company coverage

Korro Bio, Inc.(NasdaqCM: KRRO) added to Russell 2500 Growth Benchmark

Korro Bio, Inc. (NasdaqCM: KRRO) has been added to the Russell 2500 Growth Benchmark index. The company specializes in developing genetic medicines based on RNA editing, focusing on diseases like Alpha-1 Antitrypsin Deficiency. Recent news for Korro Bio includes additions to seve

Tone
Positive 74/100
Event
Market update
Published
29 Jun 2026 15:57
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Korro Bio, Inc.(NasdaqCM: KRRO) added to Russell Microcap Growth Benchmark Index

Korro Bio, Inc. (NasdaqCM: KRRO) has been included in the Russell Microcap Growth Benchmark Index. This announcement highlights the company's growing presence in the financial markets. The biopharmaceutical company focuses on developing genetic medicines based on RNA editing for

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 12:42
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Korro Bio, Inc.(NasdaqCM: KRRO) added to Russell 3000E Growth Benchmark

Korro Bio, Inc. (NasdaqCM: KRRO), a clinical-stage biopharmaceutical company focused on RNA editing for genetic medicines, has been added to the Russell 3000E Growth Benchmark. The company's lead development candidate, KRRO-110, aims to treat Alpha-1 Antitrypsin Deficiency (AATD)

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 04:52
Source
www.marketscreener.com
TradingView Direct company coverage

Korro Bio, Inc. Actuals & Estimates (NASDAQ:KRRO)

This article provides an overview of Korro Bio, Inc. (NASDAQ: KRRO) stock performance, analyst estimates, and financial data. It covers current stock price, historical highs and lows, market capitalization, upcoming earnings dates, and past financial results like revenue and net

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 00:09
Source
TradingView
TradingView Direct company coverage

KRRO Forecast — Price Target — Prediction for 2027

This article provides a forecast for Korro Bio, Inc. (KRRO) stock, including analyst price targets, past performance, and key financial data. According to analysts, KRRO has a max estimate of $30.00 and a min estimate of $8.00. The company's current stock price is $12.17, and it

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 17:09
Source
TradingView
Stock Titan Direct company coverage

Atlas Venture sells KRRO common stock in late May–June 2026 (KRRO)

Atlas Venture entities recently filed Rule 144 notices detailing proposed and executed sales of Korro Bio, Inc. (KRRO) common stock in May and June 2026. The filings show multiple transactions, including significant sales on June 22 and June 23, 2026, by Atlas Venture Fund XI, L.

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 13:42
Source
Stock Titan
Stock Titan Direct company coverage

Atlas Venture (KRRO) sells 101,579 shares on 06/23/2026, multiple Form 144 entries

Korro Bio, Inc. (KRRO) reported multiple sales of its common stock by affiliated holders, Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P., through Form 144 filings. The largest listed sale was for 101,579 shares on June 23, 2026, totaling $1,447,785.17. Ot

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 13:09
Source
Stock Titan
Investing.com Australia Direct company coverage

Form 4 Korro Bio Inc For: 24 June By Investing.com

This article from Investing.com is a regulatory filing update for Korro Bio Inc. It specifically mentions a "Form 4" filing dated June 24 and attributes the information to Reuters. The article itself is very brief, serving primarily as a notification about this financial document

Tone
Neutral 50/100
Event
Regulatory and legal
Published
25 Jun 2026 12:09
Source
Investing.com Australia
www.marketscreener.com Direct company coverage

Korro Bio Insider Sold Shares Worth $2,458,582, According to a Recent SEC Filing

An insider at Korro Bio sold shares valued at $2,458,582, as disclosed in a recent SEC filing. The company is a clinical-stage biopharmaceutical firm focused on developing genetic medicines based on RNA editing for both rare and common diseases. Korro Bio's stock performance and

Tone
Negative 38/100
Event
Market update
Published
25 Jun 2026 12:09
Source
www.marketscreener.com
Investing.com Direct company coverage

Korro Bio director Jean Francois Formela sells $2.45m in shares

Korro Bio director Jean Francois Formela sold approximately $2.46 million in company shares across three trading days in late June 2026, executed under a Rule 10b5-1 trading plan. The sales occurred as the stock traded between $13.95 and $14.98, with the current price reflecting

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 01:39
Source
Investing.com
Stock Titan Direct company coverage

Korro Bio (KRRO) director-affiliated Atlas funds sell 171K shares under 10b5-1 plan

Funds affiliated with Korro Bio director Jean Francois Formela, specifically Atlas Venture entities, sold a total of 171,405 shares of Korro Bio common stock through eight open-market transactions. These sales, executed under a pre-arranged Rule 10b5-1 trading plan adopted on Apr

Tone
Negative 36/100
Event
Market update
Published
25 Jun 2026 01:10
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 144 Korro Bio For: 23 June By Investing.com

This article from Investing.com announces the filing of Form 144 for Korro Bio on June 23. It provides limited textual content but is surrounded by extensive financial market data, including various indices, commodity prices, and stock performances. The core message is a direct r

Tone
Neutral 50/100
Event
Macro sensitivity
Published
23 Jun 2026 22:20
Source
Investing.com Canada
Stock Titan Direct company coverage

Atlas Venture sells KRRO (KRRO) stock — 2,441 and 419 shares reported

Atlas Venture has filed a Form 144, indicating proposed sales of Korro Bio, Inc. (KRRO) common stock. Atlas Venture Fund XI intends to sell 2,441 shares for $34,051.95, and Atlas Venture Opportunity Fund II plans to sell 419 shares for $5,845.05, with both sales dated May 28, 202

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 01:09
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 144 Korro Bio For: 22 June By Investing.com

This article announces the filing of Form 144 for Korro Bio on June 22nd, as reported by Investing.com. It is a brief, technical notification, typical of financial news outlets reporting on regulatory filings. The article also includes stock market data and other news headlines.

Tone
Neutral 50/100
Event
Regulatory and legal
Published
22 Jun 2026 21:42
Source
Investing.com Canada
TradingKey Direct company coverage

Korro Bio Inc (KRRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

Korro Bio Inc (KRRO) currently holds a price momentum score of 6.96, placing it 183rd in the Biotechnology & Medical Research industry. The stock is trading between resistance at $14.69 and support at $10.58, indicating potential for range-bound swing trading. Technical indicator

Tone
Positive 66/100
Event
Market update
Published
18 Jun 2026 22:09
Source
TradingKey